SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Lupus/Nephritis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (27)5/6/2001 12:17:43 PM
From: keokalani'nui  Read Replies (1) of 95
 
From the Pink Sheets, re Aslera:

Genelabs Aslera Postmarketing Safety Study for surveillance of potential renal toxicities in a larger group of patients should be required if product is approved for treatment of lupus, Arthritis Drugs Advisory Committee concludes. Efficacy is "debatable" but data trends toward clinical efficacy, committee member says.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News